诺和锐30和诺和灵30R治疗口服磺脲类药物继发失效2型糖尿病患者的临床疗效比较.docVIP

·2024 · · 短 篇 论 著 · 诺和锐30和诺和灵30R 治疗口服磺脲类药物继发失效 2型糖尿病患者的临床疗效比较 邱 凌 【摘要】 目的 比较诺和锐30和诺和灵30R对磺脲类药物继发失效的2型糖尿病 (T2DM) 患者的疗效及不良 反应方面的差异。方法 选择79例磺脲类药物继发失效的T2DM 患者，均服用一种磺脲类药物加二甲双胍、噻唑烷二 酮类或α-葡萄糖苷酶抑制剂。将患者随机分为诺和锐30组和诺和灵30R 组，分别给予诺和锐30和诺和灵30R2 次/d 治疗，治疗3个月后观察血糖控制情况及低血糖发生情况。结果 治疗后两组患者的空腹血糖 (FBG)、 餐后2 h 血糖 (2hPBG)、 糖化血红蛋白 (HbA,。) 均较治疗前显著降低，差异有统计学意义 (P0.01); 治疗后诺和锐30组的 2 hPBG及 HbA。 显著低于诺和灵30R 组，差异有统计学意义 (P0.05)。 两组患者低血糖发生率间差异无统计学意义 (P0.05); 但诺和锐30组夜间低血糖发生率显著低于诺和灵30R 组，差异有统计学意义(2.7%与7. 1%, P 0.05) 。 结论 对于磺脲类药物继发失效的T2DM 患者，诺和锐30较诺和灵30R 能更好地控制2 hPBG, 降低夜间低血 糖发生率。 【关键词】 诺和锐30;诺和灵30R; 糖尿病，2型；磺脲类药物；继发性失效 【中图分类号】 R587.1 【文献标识码】 B 【文章编号】1007-9572(2010)6C-2024-02 Efi cacy Comparison of Novomix30 and Novolin 30R in T2DM Patients with Secondary Failure of Oral Hypoglycemic A - gents QIU Ling. Department of Endocrinology,Xuhui Central Hospital,Shanghai 200031,China 【Abstract] Objective To compare the efficacy and adverse reactions of Novomix30 and Novolin 30R in patients with type 2 diabetes mellitus after secondary failure of oral hypoglycemic agents. Methods 79 patients with type 2 diabetes mellitus after secondary failure of oral hypoglycemic agents were divided into two groups at random, they were given Novomix30 and Novo- lin 30R twice daily for 3 months, blood glucose and hypoglycemia were observed. Results FBG, 2 hPBG, HbA;e decreased significantly in the two group after treatment than that before(P0.01). In Novomix30 group 2 hPBG and HbAe control was superior to Novolin 30R〔7.0±1.3 mmol/L vs.8.7±1.5 mmol/L,(6.5±1.0)% vs.(7.2±1.3)%,P0.05 〕.There was no difference between the two groups in low blood sugar incidence, but the incidence of serious nocturnal hypoglycemia was lower in Novomix30 group(2.7% vs.7. 1%,P0.05). Conclusion For patients with type 2 diabetes mellitus after seconda- ry sulfonylurea failure,Noyomix30 has better control of 2 hPBG, and the incidence of severe hypoglycemia was lower. 【Key words】 Novomix3